Panelists discuss how integrating subcutaneous (SubQ) therapies into oncology practice involves thorough economic evaluation, coordinated team education, patient engagement, and workflow adjustments ...

Panelists discuss how subcutaneous (SubQ) and intravenous (IV) oncology therapies will continue to coexist, with patient-specific factors guiding delivery method choices, while ongoing innovation and ...

Implementing subcutaneous opioid options in the emergency department significantly reduced reliance on intravenous administration.

Switching from IV to subcutaneous injection eases hard vein access, cuts clinic time, and boosts comfort with faster treatment and fewer side effects.

CHICAGO — Administering the bispecific antibody amivantamab (Rybrevant) subcutaneously rather than intravenously in combination with lazertinib (Leclaza) not only reduces administration times but also ...

PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...